证券日报网讯12月26日，建发致新（301584）在互动平台回答投资者提问时表示，公司目前的主要营业 利润来源于医疗器械产品分销业务、直销业务和服务业务(SPD管理服务为主)。公司的业务通过自主研 发和运营的"业务平台系统"等进行全流程管理，但公司本身不通过出售软件或者软件服务作为主要收入 来源。 ...

Group 1 - The core viewpoint of the article highlights that Jianfa Zhixin (301584) has been operating in the SPD business for many years, with a significant focus on SPD management services for tertiary public hospitals [1] - The gross profit margin for the company's SPD management services is projected to be in the range of 30%-40% from 2022 to 2024 [1]